<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03400176</url>
  </required_header>
  <id_info>
    <org_study_id>CVAY736Y2102</org_study_id>
    <nct_id>NCT03400176</nct_id>
  </id_info>
  <brief_title>VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib</brief_title>
  <official_title>Phase Ib Open-label Study of VAY736 and Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL) on Ibrutinib Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients enrolled to the study will have chronic lymphocytic leukemia (CLL) and are actively
      receiving ibrutinib. Patients will have either been receiving ibrutinib for one year without
      having had a complete response or patients will have developed a resistance mutation to
      ibrutinib. This study will have two parts, a dose escalation part and a dose expansion part.
      In the dose escalation part, the maximum tolerated dose (MTD) of the combination of VAY736
      with ibrutinib will be determined. Once determined, the dose expansion part of the study will
      begin.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 9, 2018</start_date>
  <completion_date type="Anticipated">August 7, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 4, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DLT rate</measure>
    <time_frame>1 year</time_frame>
    <description>To determine the incidence of DLTs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Two years</time_frame>
    <description>To determine preliminary antitumor activity of the combination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression (TTP)</measure>
    <time_frame>Two years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Chronic Lymphocytic Leukemia (CLL)</condition>
  <arm_group>
    <arm_group_label>Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Increasing doses of VAY736 in combination with a fixed dose of ibrutinib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evaluation of the MTD/RD of the combination of VAY736 and ibrutinib that was identified in dose escalation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VAY736</intervention_name>
    <description>Experimental</description>
    <arm_group_label>Dose Escalation</arm_group_label>
    <arm_group_label>Dose expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ibrutinib</intervention_name>
    <description>Approved medication</description>
    <arm_group_label>Dose Escalation</arm_group_label>
    <arm_group_label>Dose expansion</arm_group_label>
    <other_name>Imbruvica</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of CLL per the WHO classification

          -  At least 18 years of age

          -  Lack of a complete response after receiving ibrutinib for &gt; 1 year OR presence of
             known ibrutinib resistance mutation

          -  Actively receiving ibrutinib at either 420 mg (patients enrolled to the escalation
             arm) or at a stable dose for at least 2 months prior to starting study treatment
             (patients enrolled to the expansion arm)

        Exclusion Criteria:

          -  Known history of HIV

          -  Active hepatitis B or C infection

          -  Receipt of attenuated vaccine within 2 weeks prior to starting study treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>Novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>David Geffen School of Medicine at UCLA David Geffen School of Med</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Alimi NP</last_name>
      <email>nalimi@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Sarah Larson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State Comprehensive Cancer Center/James Cancer Hospital Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>614-293-5655</phone>
    </contact>
    <investigator>
      <last_name>Kerry Rodgers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology Centennial Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>615-986-7274</phone>
    </contact>
    <investigator>
      <last_name>Ian W. Flinn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah / Huntsman Cancer Institute Oncology</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maggie Rittel</last_name>
      <phone>801-213-4301</phone>
      <email>Maggie.rittel@hci.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Deborah Stephens</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 9, 2018</study_first_submitted>
  <study_first_submitted_qc>January 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 17, 2018</study_first_posted>
  <last_update_submitted>June 19, 2020</last_update_submitted>
  <last_update_submitted_qc>June 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ibrutinib</keyword>
  <keyword>VAY736</keyword>
  <keyword>Chronic lymphocytic leukemia</keyword>
  <keyword>CLL</keyword>
  <keyword>Bruton's Tyrosine Kinase</keyword>
  <keyword>BTK mutation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

